Our study revealed CDK19 as a potential biomarker in HNSCC primary tumors to predict local recurrence and disease outcomes after the initial therapy, and therefore to help risk-stratify patients. This evidence concerns the gene CDK19 and head and neck squamous cell carcinoma.